Skip to main content
OpenTrials

Clinical trial condition

Lentivirus Infections

Explore clinical trials studying Lentivirus Infections. Study availability and eligibility vary by location and protocol.

5,648 public trials 303 recruiting studies
Refine in advanced search Browse all conditions

Lentivirus Infections trial results

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • University of Colorado - The Children's Hospital of Denver Aurora, Colorado, United States
  • Stroger Hospital of Cook County Chicago, Illinois, United States
  • Tulane Medical Center New Orleans, Louisiana, United States
View Trial Details
Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 35 locations
View Trial Details
Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
View all 66 locations
View Trial Details
Completed

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
View Trial Details

Related conditions